title: Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial.
abstract: OBJECTIVE
  To assess the impact of prophylactic oral co-trimoxazole in reducing mortality in HIV positive Zambian adults being treated for pulmonary tuberculosis.
  
  
  METHODS
  Double blind placebo controlled randomised clinical trial.
  
  
  METHODS
  Two groups of antiretroviral treatment naive adults with HIV infection: patients newly diagnosed as having tuberculosis and receiving tuberculosis treatment either for the first time or for retreatment after relapse; previously treated patients not receiving treatment.
  
  
  METHODS
  Oral co-trimoxazole or matching placebo daily. Primary outcome measures Time to death and occurrence of serious adverse events related to study drug.
  
  
  RESULTS
  1003 patients were randomised: 835 (416 co-trimoxazole, 419 placebo) were receiving treatment for tuberculosis, 762 (376 co-trimoxazole, 386 placebo) of them newly diagnosed previously untreated patients and 73 (40 co-trimoxazole, 33 placebo) receiving a retreatment regimen; 168 (84 co-trimoxazole, 84 placebo) were not on treatment but had received treatment in the past. Of 835 participants receiving tuberculosis treatment, follow-up information was available for 757, with a total of 1012.6 person years of follow-up. A total of 310 (147 co-trimoxazole, 163 placebo) participants died, corresponding to death rates of 27.3 and 34.4 per 100 person years. In the Cox regression analysis, the hazard ratio for death (co-trimoxazole:placebo) was 0.79 (95% confidence interval 0.63 to 0.99). The effect of co-trimoxazole waned with time, possibly owing to falling adherence levels; in a per protocol analysis based on patients who spent at least 90% of their time at risk supplied with study drug, the hazard ratio was 0.65 (0.45 to 0.93).
  
  
  CONCLUSIONS
  Prophylaxis with co-trimoxazole reduces mortality in HIV infected adults with pulmonary tuberculosis. Co-trimoxazole was generally safe and well tolerated.
  
  
  BACKGROUND
  Current Controlled Trials ISRCTN15281875.
authors.affiliation: Medical Research Council Clinical Trials Unit, London NW1 2DA. ajn@ctu.mrc.ac.uk
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Nunn
authors.forename: Peter
authors.initials: P
authors.lastname: Mwaba
authors.forename: Chifumbe
authors.initials: C
authors.lastname: Chintu
authors.forename: Alwyn
authors.initials: A
authors.lastname: Mwinga
authors.forename: Janet H
authors.initials: JH
authors.lastname: Darbyshire
authors.forename: Alimuddin
authors.initials: A
authors.lastname: Zumla
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000008:administration & dosage*; D004311:Double-Blind Method; D004812:Epidemiologic Methods; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000401:mortality*; D006801:Humans; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000008:administration & dosage*; D014397:Tuberculosis, Pulmonary / Q000150:complications / Q000401:mortality / Q000517:prevention & control*
chemical_list: D000890:Anti-Infective Agents; D015662:Trimethoprim, Sulfamethoxazole Drug Combination